Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Burosumab

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA
    Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA

    29 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231128306616/en

    BUSINESSWIRE
    29 Nov 2023
    Share Share
    Kyowa Kirin brings rare disease drug's marketing back in house, future US growth
    Kyowa Kirin brings rare disease drug's marketing back in house, future US growth

    03 May 2023

    // Beth Snyder Bulik ENDPTS

    https://endpts.com/kyowa-kirin-brings-rare-disease-drugs-marketing-back-in-house-plots-future-us-growth/

    Beth Snyder Bulik ENDPTS
    03 May 2023
    Share Share
    Ultragenyx Announces Sale of Portion of Future N. American Royalties on Crysvita
    Ultragenyx Announces Sale of Portion of Future N. American Royalties on Crysvita

    14 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/14/2479715/20739/en/Ultragenyx-Announces-Sale-of-a-Portion-of-Future-North-American-Royalties-on-Crysvita-burosumab-for-500-Million-to-OMERS-Capital-Markets.html

    GLOBENEWSWIRE
    14 Jul 2022
    Share Share
    Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA for TIO
    Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA for TIO

    24 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220624005247/en

    BUSINESSWIRE
    24 Jun 2022
    Share Share
    Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data
    Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data

    27 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/27/2303972/20739/en/Ultragenyx-Announces-Crysvita-burosumab-and-UX143-setrusumab-Data-Presentations-at-Upcoming-American-Society-for-Bone-and-Mineral-Research-ASBMR-2021-Annual-Meeting.html

    GLOBENEWSWIRE
    27 Sep 2021
    Share Share
    New data demonstrates long-term benefit of Crysvita for XLH patients
    New data demonstrates long-term benefit of Crysvita for XLH patients

    25 Sep 2021

    // Lucy Parsons PHARMATIMES

    https://www.pharmatimes.com/news/new_data_demonstrates_long-term_benefit_of_crysvita_for_xlh_patients_1379158

    Lucy Parsons PHARMATIMES
    25 Sep 2021
    Share Share